Clinical Study
Assessment of Haemodynamic Response to Nonselective Beta-Blockers in Portal Hypertension by Phase-Contrast Magnetic Resonance Angiography
Table 1
Baseline characteristics of the study population.
| | Patient characteristic | Treatment group | value (propranolol versus carvedilol)
| | Propranolol MR | Carvedilol | All patients |
| | Number | 11 | 11 | 22 | 1.00 | | Age, years (mean ± SD) | | | | 0.99 | | Male sex, (%) | 10 (91) | 8 (73) | 18 (82) | 0.28 | | Aetiology of liver disease | | | | | | Alcoholic liver disease, (%) | 5 (45) | 3 (27) | 8 (36) | 0.39 | | Nonalcoholic fatty liver disease, (%) | 3 (27) | 4 (36) | 7 (32) | 0.66 | | Viral hepatitis, (%) | 0 (0) | 2 (18) | 2 (9.1) | 0.15 | | Other, (%) | 3 (27) | 2 (18) | 5 (23) | 0.62 | | Child-Pugh Score, (%) | | | | | | Child-Pugh A | 7 (64) | 6 (55) | 13 (59) | 0.67 | | Child-Pugh B | 2 (18) | 3 (27) | 5 (23) | 0.62 | | Child-Pugh C | 2 (18) | 2 (18) | 4 (18) | 1.00 | | Baseline heart rate, bpm | 78 (69–81) | 82 (72–94) | 79 (69–89) | 0.14 | | Systolic BP, mm Hg | 128 (116–146) | 136 (115–150) | 136 (115–150) | 0.99 | | Splenomegaly, (%) | 8 (73) | 8 (73) | 16 (73) | 1.00 | | Thrombocytopaenia, (%) | 9 (82) | 10 (91) | 19 (86) | 0.55 | | Final beta blocker dose (mg) | 160 in 7 patients
80 in 4 patients | 12.5 in all | — | | | Target beta blocker dose achieved, (%) | 7 (64) | 11 (100) | 18 (82) | 0.03 | | Completed study, (%) | 9 (82) | 10 (91) | 19 (86) | 0.55 | | Heart rate responders, (%) | 5 (56) | 4 (40) | 9 (47) | 0.50 |
|
|
rate response in propranolol group was observed in 5 patients; 3 on 80 mg of propranolol MR and 2 on 160 mg of propranolol MR.
|
